GM

Giulia Montini

Senior Scientist, Biochemistry at Heptares Therapeutics

Giulia Montini has a diverse work experience in the field of biochemistry, focusing on the biophysical and structural characterization of proteins. Their most recent position was as a Senior Scientist I at Sosei Heptares, starting in January 2022. Prior to that, they worked as a Research Scientist at the same company from October 2018 to December 2021, where they contributed to the study of G protein-coupled receptors (GPCRs) as targets for therapeutic drugs.

Before joining Sosei Heptares, Montini was a PHD Graduate Student at Birkbeck, University of London from October 2014 to November 2018. In this role, they conducted research on the biochemical, biophysical, and structural characterization of bacterial voltage-gated sodium channels, specifically looking at their interaction with analgesic drugs.

Montini began their professional experience as a Laboratory Intern at Sapienza Università di Roma from March 2012 to October 2014. Giulia also served as an Undergraduate Teaching Assistant at the Department of Biochemistry "Alessandro Rossi Fanelli" from January 2014 to September 2014, and at the Department of Biology and Biotechnology "Charles Darwin" from January 2013 to October 2013.

Overall, Giulia Montini has demonstrated a strong background in biochemistry, with a focus on protein characterization and drug targets in various academic and industry settings.

Giulia Montini's education history begins with their high school diploma, which they obtained from Liceo Scientifico Democrito between the years 2004 and 2009. After completing their high school education, they pursued a Bachelor's degree in Biotecnology at Sapienza Università di Roma from 2009 to 2012. Giulia then went on to obtain a Master's degree in Genetics and Molecular Biology from the same university, with their studies spanning from 2012 to 2014. Giulia's academic journey continued with a Doctor of Philosophy (PhD) in Biochemistry at Birkbeck, University of London, where they studied from 2014 until 2018.

Location

London, United Kingdom

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Heptares Therapeutics

Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group.